UBS Oncology Impact Fund Plans to Sell Common Shares of Werewolf Therapeutics

UBS Oncology Impact Fund, L.P. has filed a Form 144 with the SEC indicating its intention to sell 107,463 common shares of Werewolf Therapeutics, Inc. These shares were acquired through a private placement on May 4, 2021. The sale is planned to occur around October 27, 2025, with Merrill Lynch acting as the broker. The aggregate market value of the shares to be sold is approximately $190,209.51. The filing also confirms that there have been no sales of these securities in the past three months.